Connor, Clark & Lunn Investment Management (CC&L)
QNCX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Quince Therapeutics QNCX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-86
Closed -$23K – 1388
2022
Q3 		$23K Buy
+86
New +$32.8K ﹤0.01% 1078

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s QNCX Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Quince Therapeutics (QNCX) in Q4 2022, closing a stake of 86 shares — an estimated $23K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in QNCX in Q3 2022 and held it in 1 quarter. The position peaked at $23K in Q3 2022. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Quince Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 86 Quince Therapeutics shares in Q4 2022, an estimated $23K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Quince Therapeutics in Q3 2022 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Quince Therapeutics position peaked at $23K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.